A Study of CTA30X Cell Injection in the Treatment of Relapsed or Refractory CD19-positive B-line Hematological Malignancies
Latest Information Update: 02 Nov 2021
At a glance
- Drugs CTA 30X (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 05 Jan 2021 New trial record